Multiple Myeloma
Showing NaN - NaN of 109
Multiple Myeloma Trial in Worldwide (idecabtagene vicleucel, Lenalidomide, Fludarabine)
Not yet recruiting
- Multiple Myeloma
- idecabtagene vicleucel
- +3 more
-
Gilbert, Arizona
- +107 more
Sep 26, 2023
Multiple Myeloma Trial in Worldwide (Elranatamab, Lenalidomide)
Recruiting
- Multiple Myeloma
-
Benowa, Queensland, Australia
- +132 more
Jan 24, 2023
Multiple Myeloma Trial in Worldwide (JNJ-68284528, Pomalidomide, Bortezomib)
Active, not recruiting
- Multiple Myeloma
- JNJ-68284528
- +4 more
-
Birmingham, Alabama
- +87 more
Jan 17, 2023
Multiple Myeloma Trial in Worldwide (Daratumumab, Lenalidomide, Dexamethasone)
Active, not recruiting
- Multiple Myeloma
- Daratumumab
- +2 more
-
Little Rock, Arkansas
- +145 more
Jan 17, 2023
Multiple Myeloma Trial in France, Spain, United States (Daratumumab, Velcade, Pomalidomide)
Active, not recruiting
- Multiple Myeloma
- Daratumumab
- +11 more
-
Duarte, California
- +21 more
Jan 17, 2023
Multiple Myeloma Trial in Worldwide (Dara SC, Dara IV)
Active, not recruiting
- Multiple Myeloma
- Dara SC
- Dara IV
-
Boston, Massachusetts
- +145 more
Jan 17, 2023
Multiple Myeloma Trial in Worldwide (Placebo, Ixazomib)
Multiple Myeloma Trial in Korea, Republic of, Poland, Spain (Cevostamab, Lenalidomide, Tocilizumab)
Not yet recruiting
- Multiple Myeloma
- Cevostamab
- +2 more
-
Seoul, Korea, Republic of
- +4 more
Jan 11, 2023
Waldenstrom Macroglobulinemia, Multiple Myeloma, Chronic Lymphocytic Leukemia Trial in Worldwide (Iopofosine I 131 single dose,
Recruiting
- Waldenstrom Macroglobulinemia
- +8 more
- Iopofosine I 131 single dose
- +2 more
-
Redlands, California
- +42 more
Dec 30, 2022
Real-life Current Standards of Care in Relapsed and/or
Completed
- Multiple Myeloma
- No intervention
-
Tucson, Arizona
- +85 more
Dec 20, 2022
Multiple Myeloma Trial in Worldwide (Carfilzomib 20 mg/m^2, Carfilzomib 70 mg/m^2, Dexamethasone 40 mg)
Active, not recruiting
- Multiple Myeloma
- Carfilzomib 20 mg/m^2
- +4 more
-
Gilbert, Arizona
- +107 more
Dec 20, 2022
Multiple Myeloma Trial in Worldwide (Belantamab mafodotin, Lenalidomide, Dexamethasone)
Active, not recruiting
- Multiple Myeloma
- Belantamab mafodotin
- +3 more
-
Birmingham, Alabama
- +25 more
Dec 9, 2022
Multiple Myeloma Trial in Worldwide (Belantamab mafodotin, Daratumumab, Bortezomib)
Active, not recruiting
- Multiple Myeloma
- Belantamab mafodotin
- +3 more
-
Yuma, Arizona
- +150 more
Dec 9, 2022
Multiple Myeloma Trial in Worldwide (Elranatamab (PF-06863135))
Active, not recruiting
- Multiple Myeloma
- Elranatamab (PF-06863135)
-
Beverly Hills, California
- +75 more
Oct 4, 2022
Multiple Myeloma Trial in Worldwide (Carfilzomib, Dexamethasone)
Completed
- Multiple Myeloma
-
Scottsdale, Arizona
- +139 more
Sep 9, 2022